Von Willebrand Factor, recombinant (Vonvendi)

OFFICE ADMINISTRATION

FDA Approved Indications:
  • Indicated for on-demand treatment and control of bleeding episodes in adults diagnosed with von Willebrand disease
Patients must meet the following criteria for the indications above:
  • Confirmed diagnosis of von Willebrand disease requiring on-demand treatment to control bleeding episodes, AND
  • Patient is at least 18 years old, AND
  • Patient does not have known hypersensitivity to mouse or hamster proteins
Dosing:
  • For each bleeding episode, administer the first dose of Vonvendi with an approved recombinant (non-von Willebrand factor containing) factor VIII [Antihemophilic factor (Recombinant)] if factor VIII baseline levels are below 40% or are unknown.
  • Initial dose of Vonvedi is 40-80 IU per kg.  Adjust dosage based on the extent and location of bleeding
  • If recombinant factor VIII is required, give recombinant factor VIII within 10 minutes of completing Vonvendi infusion at a ration of 1:3:1
  • Administer Vonvendi within 3 hours after reconstitution
Approval:
  • One year

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.

Press Esc to cancel

El sitio Web al que está siendo transferido no es provisto por WHA. Las Condiciones de Uso y las Prácticas de Privacidad en Internet de WHA no se aplican a este sitio Web asociado que usted está usando. Revise las políticas sobre la privacidad y condiciones de uso de este sitio Web asociado. WHA no tiene control sobre la exactitud, la totalidad o la actualidad del contenido del sitio Web asociado. WHA no puede garantizar que los servicios de traducción de idiomas estarán disponibles en el sitio vinculado.

Presione «Esc» para cancelar